Supplementary Material for: Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury
收藏DataCite Commons2025-05-01 更新2024-07-27 收录
下载链接:
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Steroid_and_Ursodesoxycholic_Acid_Combination_Therapy_in_Severe_Drug-Induced_Liver_Injury/5121553/1
下载链接
链接失效反馈官方服务:
资源简介:
<i>Background:</i> Drug-induced liver injury (DILI) is the leading cause of acute severe liver disease in Western countries. Treatment strategies for DILI are still not well defined. <i>Aim:</i> We studied the safety and outcomes of steroid/ursodesoxycholic acid (UDCA) combination therapy in DILI patients. <i>Patients, Materials and Methods:</i> 15 consecutive patients with severe DILI were analyzed for clinical, biochemical and histological data. Nine patients were treated with a steroid step-down therapy with reduction of the daily dose over several weeks; 6 patients received a steroid pulse therapy for 3 days. UDCA was administered for several weeks in both groups. <i>Results:</i> Patients without histological signs of preexistent liver damage (n = 10) showed the most favorable clinical course. Bilirubin and serum transaminases dropped to <50% of peak values within 2 weeks, and normalized within 4–8 weeks. In contrast, patients with positive autoimmune antibodies (anti-nuclear antibodies and/or soluble liver antigen) and/or histological features of chronic hepatitis (n = 3) exhibited a slower reduction in bilirubin and serum transaminase levels. These patients were given immunosuppressants (steroids, azathioprine) for a further 6 months. <i>Conclusion:</i> Treatment of severe DILI with corticosteroids (both pulse and step-down therapy) and UDCA appears to be safe, and leads to a more rapid reduction in bilirubin and transaminases after DILI.
提供机构:
Karger Publishers
创建时间:
2017-06-20



